3-bromo-7-iodothieno[3,2-c]pyridin-4(5H)-one | 799293-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 3-bromo-7-iodothieno[3,2-c]pyridin-4(5H)-one
• 英文别名: 3-bromo-7-iodo-5H-thieno[3,2-c]pyridine-4-one；3-bromo-7-iodo-5H-thieno[3,2-c]pyridin-4-one
• CAS: 799293-88-2
• 化学式: C₇H₃BrINOS
• 分子量: 355.981
• InChiKey: LWSKXKRUNCZEFY-UHFFFAOYSA-N

物化性质

• 沸点：
  502.3±50.0 °C(Predicted)
• 密度：
  2.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-7-iodothieno[3,2-c]pyridin-4(5H)-one 在 ammonium hydroxide 、 四(三苯基膦)钯 、 sodium carbonate 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 为溶剂， 生成 4-amino-3-(4-methoxyphenyl)-7-(3,4,5-trimethoxyphenyl)thieno[3,2-c]pyridine
  参考文献：
  名称：

  Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases

  摘要：

  A novel class of 3,7-diphenyl-4-amino-thieno and furo[3,2-c]pyridine has been designed based on pharmacophore models of ATP competitive kinase inhibitors. Versatile synthetic methods via double Suzuki coupling to explore SAR have been established and potent inhibitors against angiogenetic targets, VEGFR2, Tie-2, and EphB4, have been successfully discovered. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.050
• 作为产物：
  描述：

  (2E)-3-(4-溴-2-噻吩基)丙烯酸 在 N-碘代丁二酰亚胺 、 二苯基磷酸 、 碘 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 邻二氯苯 、 甲苯 为溶剂， 生成 3-bromo-7-iodothieno[3,2-c]pyridin-4(5H)-one
  参考文献：
  名称：

  Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases

  摘要：

  A novel class of 3,7-diphenyl-4-amino-thieno and furo[3,2-c]pyridine has been designed based on pharmacophore models of ATP competitive kinase inhibitors. Versatile synthetic methods via double Suzuki coupling to explore SAR have been established and potent inhibitors against angiogenetic targets, VEGFR2, Tie-2, and EphB4, have been successfully discovered. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.050

文献信息

• Novel chemical compounds
  申请人：Miyazaki Yasushi

  公开号：US20080182868A1

  公开（公告）日：2008-07-31

  This invention relates to newly identified compounds for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.

  本发明涉及治疗和预防肿瘤和癌症的新型化合物，以及用于治疗与参与增殖性疾病的酪氨酸激酶失衡或不适当活性相关的增殖性疾病的方法。
• Substituted thieno and furo-pyridines
  申请人：SmithKline Beecham Corporation

  公开号：US07592352B2

  公开（公告）日：2009-09-22

  This invention relates to newly identified compounds for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.

  本发明涉及一种新识别的化合物，用于治疗和预防肿瘤和癌症，并用于治疗与酪氨酸激酶失衡或不适当活性有关的增殖性疾病的方法。
• [EN] NOVEL CHEMICAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004100947A3

  公开（公告）日：2005-03-24
• Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations
  作者：Kerry Murphy-Benenato、Hongming Wang、Helen M. McGuire、Hajnalka E. Davis、Ning Gao、D. Bryan Prince、Haris Jahic、Suzanne S. Stokes、P. Ann Boriack-Sjodin

  DOI：10.1016/j.bmcl.2013.11.007

  日期：2014.1

  In an attempt to identify novel inhibitors of NAD(+)-dependent DNA ligase (LigA) that are not affected by a known resistance mutation in the adenosine binding pocket, a detailed analysis of the binding sites of a variety of bacterial ligases was performed. This analysis revealed several similarities to the adenine binding region of kinases, which enabled a virtual screen of known kinase inhibitors. From this screen, a thienopyridine scaffold was identified that was shown to inhibit bacterial ligase. Further characterization through structure and enzymology revealed the compound was not affected by a previously disclosed resistance mutation in Streptococcus pneumoniae LigA, Leu75Phe. A subsequent medicinal chemistry program identified substitutions that resulted in an inhibitor with moderate activity across various Gram-positive bacterial LigA enzymes. (C) 2013 Elsevier Ltd. All rights reserved.
• NOVEL CHEMICAL COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1620094A2

  公开（公告）日：2006-02-01